tiprankstipranks
SCYNEXIS (SCYX)
NASDAQ:SCYX
US Market
SCYX
SCYNEXIS
RESEARCH TOOLSreports
Want to see SCYX full AI Analyst Report?

SCYNEXIS (SCYX) Stock News & Sentiment

1,565 Followers
SCYNEXIS Director Steven Gilman Announces Board Retirement
Premium
Company Announcements
SCYNEXIS Director Steven Gilman Announces Board Retirement
11d ago
8K
SCYX
Scynexis: Strategic Pivot to Rare Disease With ADPKD Asset, Strengthened Balance Sheet, and Antifungal Optionality Support Buy Rating and $4 Target
Premium
Ratings
Scynexis: Strategic Pivot to Rare Disease With ADPKD Asset, Strengthened Balance Sheet, and Antifungal Optionality Support Buy Rating and $4 Target
17d ago
SCYX
SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease
Premium
Company Announcements
SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease
1M ago
8K
SCYX
SCYNEXIS Acquires AMPK Program, Expands Rare Disease Pipeline
Premium
Company Announcements
SCYNEXIS Acquires AMPK Program, Expands Rare Disease Pipeline
1M ago
8K
SCYX
SCYNEXIS Raises $40 Million in Strategic Private Placement
Premium
Company Announcements
SCYNEXIS Raises $40 Million in Strategic Private Placement
1M ago
8K
SCYX
Buy Rating on Scynexis Backed by Strong Cash Runway and Differentiated Next‑Generation Antifungal SCY‑247 Opportunity
Premium
Ratings
Buy Rating on Scynexis Backed by Strong Cash Runway and Differentiated Next‑Generation Antifungal SCY‑247 Opportunity
1M ago
SCYX
SCYNEXIS Halts Phase 3 MARIO Trial, Raising New Questions for Ibrexafungerp’s Growth Path
Premium
Company Announcements
SCYNEXIS Halts Phase 3 MARIO Trial, Raising New Questions for Ibrexafungerp’s Growth Path
4M ago
SCYX
More SCYX News >

SCYX News on the Web

Scynexis: Strategic Pivot to Rare Disease With ADPKD Asset, Strengthened Balance Sheet, and Antifungal Optionality Support Buy Rating and $4 Target
TipRanks News
Bullish
Squadron Capital Management LLC Acquires 7,608,695 Shares in SCYNEXIS Inc
GuruFocus News
Bullish
SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease
TipRanks News
Neutral
SCYNEXIS Inc Corporate Update Call Transcript
GuruFocus News
Neutral
SCYNEXIS Acquires AMPK Program, Expands Rare Disease Pipeline
TipRanks News
Neutral
SCYNEXIS Raises $40 Million in Strategic Private Placement
TipRanks News
Neutral
SCYNEXIS Secures Rights to PXL770 in a Deal Worth Up to $196 Million—Major Milestone for Rare Kidney Disease Pipeline
Market Chameleon
Neutral
Poxel To Sell PXL770 To Scynexis For Up To $196 Mln; Shares Up
rttnews
Bullish

News Score - Last 7 Days

Positive
SCYX
Sector Average
Media Buzz
This Week2 articles
Weekly Average2.5 articles
News Sentiment
This Week100%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is SCYX’s Media Buzz Sentiment?
2 articles about SCYX were published this week. In an average week, 2.5 articles are published.
    What is SCYX’s weekly average amount of articles?
    In an average week, 2.5 articles about SCYX are published.
      What is SCYX’s News Sentiment?
      100% of articles about SCYX were positive this week, compared to its sector average of 70%.
        Healthcare Stocks that are Trending in the News
        TVTXTravere Therapeutics
        HVOOpen Orphan Plc
        PBMPsyence Biomedical
        QDELQuidelOrtho
        Showing the stocks with the most bullish news sentiment over the past week